Long-term efficacy, safety and drug survival of ustekinumab in a spanish cohort of patients with moderate to severe plaque psoriasis

Dermatology

Volumn 230, Issue 1, 2015, Pages 46-54

  Puig, Lluís ^a   Ruiz Salas, Veronica ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Biological therapy; Long term efficacy; Psoriasis; Safety; Survival; Ustekinumab

Indexed keywords

ADALIMUMAB; ANTIINFECTIVE AGENT; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; USTEKINUMAB; DERMATOLOGICAL AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; AVULSION INJURY; BLEPHARITIS; BODY MASS; BODY WEIGHT; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; DISEASE SEVERITY; DRUG DOSE INTENSIFICATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GENDER; HAND WART; HOSPITAL ADMISSION; HUMAN; INFECTION; INFLUENZA; INTENTION TO TREAT ANALYSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBESITY; PARONYCHIA; PERTUSSIS; PHARYNGOAMYGDALITIS; POLYARTHRITIS; PRIORITY JOURNAL; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; SCABIES; SPAIN; SPONDYLITIS; SUPERINFECTION; SURVIVAL; TOOTH ABSCESS; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT INFECTION; VERY ELDERLY; ADOLESCENT; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; MEDICATION COMPLIANCE; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; PSORIASIS; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; COHORT STUDIES; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PSORIASIS; RETROSPECTIVE STUDIES; SPAIN; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84922979342     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000366499     Document Type: Article

References (20)

1. Kimball AB, Gordon KB, Fakharzadeh S, Yeilding N, Szapary PO, Schenkel B, et al: Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol 2012; 166:861-872.
2. Reich K, Papp KA, Griffiths CE, Szapary PO, Yeilding N, Wasfi Y, et al; PHOENIX 1, PHOENIX 2, and ACCEPT investigators: An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol 2012; 11: 300-312.
3. Kimball AB, Papp KA, Wasfi Y, Chan D, Bis-sonnette R, Sofen H, et al; PHOENIX 1 Investigators: Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol 2013; 27:1535-1545.
4. Garcia-Doval I, Carretero G, Vanaclocha F, Ferrandiz C, Daudén E, Sánchez-Carazo JL, et al: Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. Arch Der-matol 2012; 148:463-470.
5. Laws PM, Downs AM, Parslew R, Dever B, Smith CH, Barker JN, et al: Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the UK and Ireland. Br J Dermatol 2012; 166:189-195.
6. Ruiz Salas V, Puig L, Alomar A: Ustekinumab in clinical practice: response depends on dose and previous treatment. J Eur Acad Dermatol Venereol 2012; 26:508-513.
7. Gisondi P, Conti A, Galdo G, Piaserico S, De Simone C, Girolomoni G: Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study. Br J Dermatol 2013; 168:1124-1127.
8. Puig L, Carrascosa JM, Carretero G, de la Cueva P, Lafuente-Urrez RF, Belinchón I, et al; Grupo Español de Psoriasis de la Acade-mia Española de Dermatología y Venereolo-gía: Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: On efficacy and choice of treatment. Actas Dermosifiliogr 2013; 104:694-709.
9. Carrascosa JM, Vilavella M, Garcia-Doval I, Carretero G, Vanaclocha F, Daudén E, et al: Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry. J Eur Acad Dermatol Venereol 2014; 28:907-914.
10. Lebwohl M, Yeilding N, Szapary P, Wang Y, Li S, Zhu Y, Reich K, et al: Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. J Am Acad Dermatol 2010; 63:571-579.
11. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al; PHOENIX 1 Study Investigators: Efficacy and safety of ustekin-umab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371:1665-1674.
12. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al; PHOENIX 2 Study Investigators: Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371:1675-1684.
13. Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, et al; ACCEPT Study Group: Comparison of uste-kinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362:118-128.
14. Clemmensen A, Spon M, Skov L, Zachariae C, Gniadecki R: Responses to ustekinumab in the anti-TNF agent-naïve vs anti-TNF agentexposed patients with psoriasis vulgaris. J Eur Acad Dermatol Venereol 2011; 25:1037-1040.
15. Gniadecki R, Kragballe K, Dam TN, Skov L: Comparison of drug survival rates for adalim-umab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol 2011; 164:1091-1096.
16. Esposito M, Gisondi P, Cassano N, Ferrucci G, Del Giglio M, Loconsole F, et al: Survival rate of anti-TNF alpha treatments for psoriasis in routine dermatological practice: a mul-ticenter observational study. Br J Dermatol 2013; 169:666-672.
17. McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, et al; PSUMMIT 1 Study Group: Efficacy and safety of uste-kinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicen-tre, double-blind, placebo-controlled PSUM-MIT 1 trial. Lancet 2013; 382:780-789.
18. De Souza A, Ali-Shaw T, Reddy SM, Fioren-tino D, Strober BE: Inflammatory arthritis following ustekinumab treatment for psoriasis: a report of two cases. Br J Dermatol 2013; 168:210-212.
19. Rozenbaum M, Boulman N, Slobodin G, Ayubkhanov E, Rosner I: Polyarthritis flare complicating rheumatoid arthritis infliximab therapy: a paradoxic adverse reaction. J Clin Rheumatol 2006; 12:269-271.
20. Talamonti M, Galluzzo M, Bianchi L, Boca AN, Costanzo A, Chimenti S: What happened after the clinical trials: long-term safety and efficacy of ustekinumab in daily clinical practice. Dermatology 2014; 229: 324-332.